OpenAI buys Orchestra Bio to add drug-programme agents to its Rosalind suite

OpenAI has acquired Orchestra Bio, a company that builds software to coordinate drug development work across biopharma teams. OpenAI announced the deal on 20 October 2026 and is combining Orchestra's team and platform with Rosalind, its life sciences brand. Price and terms were not disclosed.

What Orchestra does

Orchestra's platform pairs people with AI agents. The agents take on the monitoring: keeping tabs on studies and campaigns and noticing when something changes. Scientists and programme leaders keep the decisions.

The useful part is what happens when a problem appears. If, say, a manufacturing batch fails and puts a clinical trial at risk, the agents work out which activities and timelines are affected, pull together the relevant information and lay out the options for responding. The goal, as OpenAI puts it, is to tie what scientists learn in the lab to the programme decisions and studies that follow.

Orchestra's founder, Ashoka Rajendra, is joining OpenAI with the company, according to Runtime Wire, which also reports that Orchestra had raised $20 million before the deal.

Where it fits in Rosalind

Rosalind is already a set of products rather than a single model. It includes GPT-Rosalind, a model built for reasoning through biology and chemistry questions, and Rosalind Workbench, which links that model to scientific tools and data so researchers can analyse results and plan experiments. Unite.AI adds that Workbench is in research preview, that there is a Codex integration for building reusable research workflows, and that API access requires an eligibility review.

Most of that is aimed at early research, helping scientists plan experiments and make sense of results. Orchestra pushes Rosalind further down the pipeline, into the operational work of moving a programme towards the clinic. OpenAI points out that drug development typically takes 10 to 15 years from target discovery to US approval, and that long, messy middle is where Orchestra's agents operate.

OpenAI's announcement also points to its existing work with Novo Nordisk and Moderna.

The bigger picture

Until recently, lab and R&D software buyers were choosing between specialist vendors such as Benchling, Dotmatics or Revvity Signals. This deal, landing the same week as Revvity's LabGistics launch and days after Benchling's Science Foundries, shows a frontier AI lab competing for the same workflow territory. For specialist vendors the pressure is to prove their domain depth and data foundations are worth more than a general model with life sciences tooling on top.